Invivyd, Inc. (IVVD)
NASDAQ: IVVD · Real-Time Price · USD
0.8609
+0.0231 (2.76%)
At close: May 13, 2025, 4:00 PM
0.9153
+0.0544 (6.32%)
Pre-market: May 14, 2025, 7:19 AM EDT
Invivyd Employees
As of December 31, 2024, Invivyd had 100 total employees, including 99 full-time and 1 part-time employees. The number of employees increased by 5 or 5.26% compared to the previous year.
Employees
100
Change (1Y)
5
Growth (1Y)
5.26%
Revenue / Employee
$253,840
Profits / Employee
-$1,699,250
Market Cap
103.27M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 100 | 5 | 5.26% |
| Dec 31, 2023 | 95 | 9 | 10.47% |
| Dec 31, 2022 | 86 | -17 | -16.50% |
| Dec 31, 2021 | 103 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
IVVD News
- 1 day ago - Invivyd to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference - GlobeNewsWire
- 2 days ago - Invivyd Announces New Pipeline Discovery Program Focused on Monoclonal Antibody Treatment for Measles - GlobeNewsWire
- 6 days ago - Invivyd to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025 - GlobeNewsWire
- 23 days ago - Invivyd Announces $30M Non-dilutive Loan Facility with Silicon Valley Bank - GlobeNewsWire
- 6 weeks ago - Invivyd Appoints Ajay Royan, Founder of Mithril Capital, to its Board of Directors - GlobeNewsWire
- 7 weeks ago - Invivyd Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Recent Business Highlights - GlobeNewsWire
- 2 months ago - Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Currently Dominant SARS-CoV-2 Variant LP.8.1 - GlobeNewsWire
- 2 months ago - FDA Rejects Invivyd's Request To Expand Emergency Authorization For Preventive COVID-19 Antibody For Immunocompromised Patients - Benzinga